Amgen's Prolia, which dominated the osteoporosis treatment market, is further strengthening its dominance system. Sales are expected to surpass 100 billion won by the end of this year. Evenity, a generic for Prolia, is also rapidly increasing its sales. It has grown into the second-largest product in the osteoporosis treatment market in less than two years since the salary was applied in December 2020. According to IQVIA, a pharmaceutical market research firm, Prolia's cumulative sales in the third quarter of this year were 83.8 billion won. It increased by 28.6% compared to the same period last year-on-year. Prolia is a mechanism drug that inhibits bone absorption. It has become the first standard treatment for oste